Seres Therapeutics 与雀巢健康科学签署了一份不具约束力的谅解备忘录，由 Seres 销售细菌感染药物 Vowst。 Seres Therapeutics and Nestlé Health Science sign a non-binding MoU for Seres to sell bacterial infection drug Vowst.

Seres Therapeutics 与雀巢健康科学签署了一份不具约束力的谅解备忘录，Seres 将出售其细菌感染药物 Vowst 及相关知识产权。 Seres Therapeutics and Nestlé Health Science have signed a non-binding MoU for Seres to sell its bacterial infection drug, Vowst, and related intellectual property rights. 该交易需获得最终批准，预计将在 90 天内完成，Seres 将获得资本注入，包括一笔未公开的预付款。 The deal, subject to final approval, is expected to be completed within 90 days, with Seres receiving capital infusions, including an undisclosed upfront payment. 所得收益将用于偿还 Seres 的债务以及资助微生物组候选产品 SER-155 等的进展。 Proceeds will be used to repay Seres' debt and fund advancement of microbiome product candidates SER-155 and others.